HRA005542
Title:
A Pilot Phase II Trial of Neoadjuvant Chemoimmunotherapy with Camrelizumab plus Nab-paclitaxel and Cisplatin (NeoCPC) in Resectable Locally Advanced Squamous Cell Carcinoma of the Head and Neck
Release date:
2023-09-25
Description:
NeoCPC showed potential efficacy in terms of radiographic and pathologic response, with an acceptable safety profile, in patients with resectable locally advanced HNSCC (NCT04826679). We evaluated the efficacy and safety of neoadjuvant camrelizumab in combination with nab-paclitaxel and cisplatin (NeoCPC) in patients with locally advanced HNSCC.
Data Accessibility:   
Controlled access Request Data
BioProject:
Study type:
Disease Study
Disease name:
head and neck cancer
Data Access Committee

For each controlled access study, there is a corresponding Data Access Committee(DAC) to determine the access permissions. Access to actual data files is not managed by NGDC.


DAC NO.:
DAC name:
KA8F
Contact person:
Hong xiaoyu
Email:
1196678774@qq.com
Description:
KA8F_HSNCC
Individuals & samples
Submitter:   liu xuekui / liuxk@sysucc.org.cn
Organization:   Sun Yat-Sen University Cancer Centre
Submission date:   2023-07-26
Requests:   1